Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
TOKYO, March 19, 2014
TOKYO, March 19, 2014 /PRNewswire/ --Astellas Pharma Inc. ("Astellas"; Tokyo:
4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company,
Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced
the companies would form a compound library sharing partnership for
approximately 400,000 selected compounds. The collaboration enables each party
to promote innovative new medicine research and development. This is the first
time that a compound library partnership of this scale has been formed in
Astellas and Daiichi Sankyo have compound libraries that are the basis for
their drug discovery research, and through High Throughput Screening (HTS)^1),
the companies can quickly and effectively search for potentially beneficial
compounds to develop innovative new drugs. Extensive, diverse, and
high-quality compound libraries, such as the joint Astellas/Daiichi Sankyo
libraries, are crucial to successful drug discovery.
This partnership will give each company access to qualitatively different
compound libraries—which have been developed based on the targeting disease
strategies of each company—allowing both companies to implement broader HTS to
generate innovative new drugs.
Under this partnership, Astellas and Daiichi Sankyo will exchange
approximately 400,000 selected compounds, including a significant number of
proprietary synthetic compounds, from their respective compound libraries.
Beginning April 1, 2014, for a period of three years, both Astellas and
Daiichi Sankyo will be able to implement broad HTS using the shared compounds
without restrictions on targeted disease areas. In line with the partnership,
each company will disclose sufficient information to allow the receiving
company to implement HTS independently.
If, as a result of HTS, the receiving company identifies a candidate compound
to be used for a new drug discovery, the receiving company may carry out
development and commercialization of the innovative new drug with an
indication for any human diseases from the compound pursuant to the terms of
Astellas and Daiichi Sankyo have each set forth a corporate philosophy to
contribute to the health of people around the world. Through this partnership,
both companies aim to effectively utilize each other's assets and knowledge
beyond the framework of one pharmaceutical company, and accelerate open
innovation while taking advantage of their own internal strengths to provide
innovative new drugs.
^1) A method of high-speed screening of molecules that respond to potential
drug targets from an extremely large number of compounds, through an advanced
systemization method. HTS plays an important role in early drug discovery and
is an effective technique for finding good candidate compounds that lead to
SOURCE Astellas Pharma Inc.
Contact: Astellas Pharma Inc., Corporate Communications, TEL: 03-3244-3201,
http://www.astellas.com/en; Daiichi Sankyo Company, Limited, Corporate
Communications, Media: 03-6225-1126, IR related: 03-6225-1125,
Press spacebar to pause and continue. Press esc to stop.